Serum Anti-Acetylcholine Receptor Antibody, Interleukin-2 and Soluble Interleukin-2 Receptor Level in Myasthenia Gvavis

J Korean Neurol Assoc > Volume 14(3); 1996 > Article

Journal of the Korean Neurological Association 1996;14(3): 773-780.

중즌근무력증에서 혈청 항아세틸콜린 수용체 항체, Interleukin-2 및 가용성 Interleukin-2 수용체 농도의 변동

임정근, 박준형, 유영수, 이상도, 박영춘

계명대학교 의과대학 신경과학교실

Serum Anti-Acetylcholine Receptor Antibody, Interleukin-2 and Soluble Interleukin-2 Receptor Level in Myasthenia Gvavis

Jeong-Geun Lim, M.D., Jun-Hyung Park, M.D., Young-Soo You, M.D., Sang-Do Yi, M.D., Young-Choon Park, M.D.

Department of neurology, Keimyung University School of Medicine

Abstract

Objective/Background : Serum levels of anti-acetylcholine receptor antibody (AChR-Ab), interleukin-2 (IL-2) and soluble interleukin-2 receptor (sIL-2R) may represent markers of disease severity in myasthenia gravis (MG). This study was performed to evaluate the correlations between disease severity and immunological parameters such as serum AChR-Ab, IL-2 and sIL-2R level and between each immunological parameters. Methods : Serum levels of AChR-Ab, IL-2 and sIL-2R were measured in 30 MG patients and in 22 healthy controls. Results : Serum levels of AChR-Ab and sIL-2R were higher in MG than in healthy controls (p< 0,01) . The occurrence of IL-2 positive serum samples was 46.7% in MG but none in controls. There were no significant correlations between disease severity and immunological parameters and between each immunological parameters. Conclusions : Serum IL-2 and sIL-2R levels may not represent markers of disease severity in MG, In order to further document the correlation between each parameters, follow-up of individual patients with serial serum samplings may be necessary.